Suppr超能文献

非酒精性脂肪性肝病(NAFLD)各阶段疾病状态转变概率:配对肝活检或影像学研究的系统评价和荟萃分析。

Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies.

机构信息

Center for Value-Based Care Research, Cleveland Clinic Community Care, Cleveland Clinic, Cleveland, Ohio.

Center for Value-Based Care Research, Cleveland Clinic Community Care, Cleveland Clinic, Cleveland, Ohio; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.

出版信息

Clin Gastroenterol Hepatol. 2023 May;21(5):1154-1168. doi: 10.1016/j.cgh.2022.07.033. Epub 2022 Aug 4.

Abstract

BACKGROUND & AIMS: We conducted a meta-analysis to summarize the rates of progression to and regression of nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and fibrosis in adults with nonalcoholic fatty liver disease (NAFLD).

METHODS

We searched PubMed/Medline and 4 other databases from 1985 through 2020. We included observational studies and randomized controlled trials in any language that used liver biopsy or imaging to diagnose NAFLD in adults with a follow-up period ≥48 weeks. Rates were calculated as incident cases per 100 person-years and pooled using the random-effects Poisson distribution model. Heterogeneity was assessed using the I statistic.

RESULTS

We screened 9744 articles and included 54 studies involving 26,738 patients. Among observational studies, 20% of healthy adults developed NAFL (incidence rate, 4.8/100 person-years) while 21% of people with fatty liver had resolution of NAFL (incidence rate, 2.4/100 person-years) after a median of approximately 4.5 years. In addition, 31% of patients developed NASH after 4.7 years (incidence rate, 7.4/100 person-years), whereas in 29% of those with NASH, resolution occurred after a median of 3.5 years (incidence rate, 5.1/100 person-years). Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3, and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from randomized controlled trials were higher than those from observational studies.

CONCLUSIONS

In our meta-analysis, progression to NASH was more common than regression from NASH. Rates of fibrosis progression were similar across baseline stage, but patients with advanced fibrosis were more likely to regress than those with mild fibrosis.

摘要

背景与目的

我们进行了一项荟萃分析,以总结非酒精性脂肪性肝病(NAFLD)成人中进展为非酒精性脂肪性肝炎(NASH)、逆转和纤维化的比率。

方法

我们从 1985 年至 2020 年在 PubMed/Medline 和其他 4 个数据库中进行了检索。我们纳入了任何语言的观察性研究和随机对照试验,这些研究使用肝活检或影像学在随访时间≥48 周的成人中诊断为 NAFLD。使用随机效应泊松分布模型计算比率,并以每 100 人年的发生率表示。使用 I 统计量评估异质性。

结果

我们筛选了 9744 篇文章,纳入了 54 项涉及 26738 名患者的研究。在观察性研究中,20%的健康成年人出现了 NAFL(发生率为 4.8/100 人年),而在大约 4.5 年后,21%的脂肪肝患者的 NAFL 得到了缓解(发生率为 2.4/100 人年)。此外,31%的患者在 4.7 年后出现了 NASH(发生率为 7.4/100 人年),而在 29%的 NASH 患者中,在中位数为 3.5 年后出现了缓解(发生率为 5.1/100 人年)。进展到 1 个纤维化阶段的时间分别为 F0、F1、F2 和 F3 为 9.9、10.3、13.3 和 22.2 年。逆转 1 个阶段的时间分别为 F4、F3、F2 和 F1 为 21.3、12.5、20.4 和 40.0 年。来自随机对照试验的估计率高于来自观察性研究的估计率。

结论

在我们的荟萃分析中,进展为 NASH 比从 NASH 缓解更为常见。在基线阶段,纤维化进展的比率相似,但进展到晚期纤维化的患者比进展到轻度纤维化的患者更有可能缓解。

相似文献

1
Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies.
Clin Gastroenterol Hepatol. 2023 May;21(5):1154-1168. doi: 10.1016/j.cgh.2022.07.033. Epub 2022 Aug 4.
3
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.
4
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Eur J Cancer. 2022 Sep;173:250-262. doi: 10.1016/j.ejca.2022.06.051. Epub 2022 Aug 6.
5
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10. doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28.
7
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101816. doi: 10.1016/j.clinre.2021.101816. Epub 2021 Oct 2.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

引用本文的文献

1
Cost-effectiveness of transient elastography for liver fibrosis screening in Thai patients with diabetes mellitus.
World J Gastroenterol. 2025 Aug 28;31(32):110333. doi: 10.3748/wjg.v31.i32.110333.
3
Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.
Med J Aust. 2025 Sep 1;223(5):268-276. doi: 10.5694/mja2.70008. Epub 2025 Jul 28.
5
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD.
Immunotargets Ther. 2025 Jul 11;14:719-733. doi: 10.2147/ITT.S530451. eCollection 2025.
6
Value-Based Pricing of Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease.
JAMA Netw Open. 2025 Jun 2;8(6):e2517122. doi: 10.1001/jamanetworkopen.2025.17122.
7
Decoding survival in MASLD: the dominant role of metabolic factors.
Diabetol Metab Syndr. 2025 Jun 18;17(1):226. doi: 10.1186/s13098-025-01802-9.
10
CDT1 is a Potential Therapeutic Target for the Progression of NAFLD to HCC and the Exacerbation of Cancer.
Curr Genomics. 2025;26(3):225-243. doi: 10.2174/0113892029313473240919105819. Epub 2024 Oct 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验